What is the appropriate work-up for polycythemia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 5, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Polycythemia Work-Up

Begin with hemoglobin/hematocrit measurement and JAK2 mutation testing if the patient has hemoglobin >18.5 g/dL (men) or >16.5 g/dL (women), particularly when accompanied by leukocytosis, thrombocytosis, or symptoms suggestive of polycythemia vera. 1, 2

Initial Assessment

When evaluating polycythemia, first determine if this is isolated erythrocytosis or accompanied by other cytopenias:

  • If isolated polycythemia: Prioritize excluding secondary causes (hypoxia, smoking, sleep apnea, erythropoietin-secreting tumors, medications like androgens or SGLT2 inhibitors) before pursuing genetic testing 3, 4
  • If polycythemia with leukocytosis or thrombocytosis: Immediately test for JAK2 mutations and serum erythropoietin levels, as this pattern strongly suggests polycythemia vera 3

Diagnostic Criteria for Polycythemia Vera

The WHO criteria require both major criteria plus one minor criterion, OR the first major criterion plus two minor criteria 1, 2:

Major Criteria:

  1. Hemoglobin ≥18.5 g/dL (men) or ≥16.5 g/dL (women), OR documented sustained increase of ≥2 g/dL from baseline that cannot be attributed to iron deficiency correction
  2. Presence of JAK2 V617F or JAK2 exon 12 mutation (found in >95% of PV cases) 1, 4

Minor Criteria:

  1. Bone marrow biopsy showing hypercellularity with trilineage growth (panmyelosis)
  2. Serum erythropoietin level below normal reference range
  3. Endogenous erythroid colony formation in vitro 1, 2

Algorithmic Approach

Step 1: Confirm True Polycythemia

  • Verify hemoglobin/hematocrit elevation is sustained on repeat testing
  • Important caveat: Iron deficiency can mask polycythemia by lowering hemoglobin; in clinical practice, you can make a working diagnosis of PV despite not meeting WHO hemoglobin thresholds if iron deficient, though formal diagnosis for research requires demonstrating criteria after iron replacement 2

Step 2: Look for Clinical Clues

  • PV-specific symptoms: Pruritus (33%), erythromelalgia (5.3%), visual disturbances (14%), splenomegaly (36%), headache 4
  • Associated findings: Thrombocytosis (53%), leukocytosis (49%), hypochromic microcytic RBCs (from iron deficiency) 4, 5
  • Thrombotic history: 16% have prior arterial thrombosis, 7% venous thrombosis (including unusual sites like splanchnic veins) 4

Step 3: Order Targeted Testing

  1. JAK2 V617F mutation (first-line genetic test)
  2. Serum erythropoietin level (low in PV, elevated in secondary causes)
  3. Complete blood count with differential (assess for leukocytosis, thrombocytosis, RBC morphology)
  4. If JAK2 V617F negative but high suspicion: Test for JAK2 exon 12 mutations 1, 2

Step 4: Bone Marrow Biopsy

  • Always required for definitive diagnosis, as genetic mutations are not disease-defining and morphologic evaluation is essential to distinguish MPN subtypes 6
  • Shows hypercellularity with panmyelosis in PV
  • Look for teardrop cells suggesting myelofibrosis progression 6

Step 5: Exclude Secondary Causes

If JAK2 negative or isolated erythrocytosis without other cytopenias:

  • Hypoxia evaluation: Pulse oximetry, arterial blood gas, sleep study if indicated
  • Smoking history and cessation status
  • Medication review: Androgens, SGLT2 inhibitors, erythropoietin-stimulating agents
  • Imaging: Abdominal ultrasound or CT to exclude erythropoietin-secreting tumors (renal cell carcinoma, hepatocellular carcinoma, hemangioblastoma) 3, 5
  • Consider hereditary erythrocytosis if family history present and secondary causes excluded 3

Common Pitfalls

  • Don't rely solely on hemoglobin/hematocrit at high altitude: Many patients may have physiologic adaptation rather than PV; use the distinct CBC pattern (leukocytosis, thrombocytosis, microcytic RBCs) to better select patients for JAK2 testing 5
  • Don't skip bone marrow biopsy: Genetic testing alone is insufficient; morphologic confirmation is mandatory 6
  • Don't delay workup: Untreated polycythemia increases risk of myocardial infarction and stroke 7
  • Remember relative polycythemia: Chronic plasma volume contraction can cause apparent polycythemia without true red cell mass increase 3

The alternative diagnostic pathway (first major criterion plus two minor criteria) captures true PV cases that may be JAK2-negative or have low mutation burden, though this represents <5% of cases 2, 4.

References

6
Research

Myeloproliferative neoplasms: Diagnostic workup of the cythemic patient.

International journal of laboratory hematology, 2019

Related Questions

Which ICD‑10‑CM code should be used for a patient with mildly elevated red blood cell count and hematocrit when no specific cause such as dehydration, high altitude, or a primary myeloproliferative disorder is identified?
In a patient with an elevated hematocrit (~57%) and hemoglobin 16.9 g/dL, what management steps should be taken while awaiting JAK2 mutation testing?
What is the recommended approach to diagnosing and treating polycythemia, including workup for primary versus secondary causes and appropriate management strategies?
Which blood test should be performed to exclude polycythemia vera?
What is the recommended management for a patient with pulmonary hypertension and relative erythrocytosis (hemoglobin 16.7 g/dL, hematocrit 52 %, red blood cell count 5.89 ×10^6/µL)?
In a stable 45‑year‑old man with known atrioventricular nodal reentrant tachycardia presenting with a regular narrow‑complex tachycardia at 150–170 bpm, is it appropriate to give an 18‑mg rapid IV bolus of adenosine as the first dose, and what should be the next step in management after the tachycardia recurs?
What is the most common cause of epistaxis in children?
In a 45-year-old man with a history of atrioventricular nodal re‑entrant tachycardia presenting with a regular narrow‑complex tachycardia at 150–170 bpm, could the rhythm be atypical atrial flutter?
What is the appropriate dosing and safety considerations for fosfomycin in a patient with chronic kidney disease?
In a patient with a history of mitral valve surgery who now presents with a regular narrow‑complex tachycardia at 150–170 bpm, what is the recommended diagnostic and initial management approach?
What is the appropriate emergency management for a patient with acute alcohol poisoning?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.